Precise Ratiometric Drug Delivery for the Treatment of Triple-Negative Breast Cancer.

ABSTRACT: Triple-negative breast cancer (TNBC) remains a significant clinical challenge due to its high aggressiveness, poor prognosis, and lack of targeted therapies. Combining paclitaxel (PTX) with rapamycin (RAP), a PI3K/AKT/mTOR pathway inhibitor, has shown promise in preclinical and clinical studies, but the approach is limited by pharmacokinetic disparities and toxicity concerns. Here, we introduce Rapaxane, a formulation composed of polymeric micelles coloaded with oligo(lactic acid)₈ conjugated prodrugs of PTX (oLA₈-PTX) and RAP (oLA₈-RAP) at an optimized synergistic ratio (5:1). We evaluated the efficacy of Rapaxane in vitro and in preclinical TNBC models, comparing it to the benchmark formulation Abraxane, the combination of parent drugs, and monotherapies

SUBMITTER: Kang RH 

PROVIDER: S-EPMC12676740 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature